证券代码：300813 证券简称：泰林生物 公告编号：2025-083 浙江泰林生物技术股份有限公司（以下简称"公司"）全资子公司浙江泰林 生命科学有限公司（以下简称"泰林生命科学"）、浙江泰林医学工程有限公司（以 下简称"泰林医学工程"）于近期共取得了 3 项专利证书，具体情况如下： | 序号 | 专利名称 | 专利类型 | 申请号 | 授权公告日 | 专利权人 | | --- | --- | --- | --- | --- | --- | | 1 | 一种过氧化氢汽化消毒机 | 实用新型 | 2024225569186 | 2025/11/7 | 泰林医学工程 | | 2 | 一种西林瓶翻转装置 | 实用新型 | 2024227562302 | 2025/11/7 | 泰林医学工程 | | 3 | 一种多用途的虹吸旋盖 | 实用新型 | 2024232559916 | 2025/11/7 | 泰林生命科学； 江苏宏众百德 生物科技有限 公司 | 上述专利的取得不会对公司及全资子公司泰林生命科学、泰林医学工程近期 生产经营产生重大影响，但有利于公司及全资子公司泰林生命科学、泰林医学工 程进一步完善知识产权保 ...

Core Viewpoint - Tailin Bio (300813) announced the acquisition of three invention patent certificates by its wholly-owned subsidiaries, Zhejiang Tailin Life Science Co., Ltd. and Zhejiang Tailin Medical Engineering Co., Ltd. [1] Company Summary - Tailin Bio's subsidiaries have recently obtained three invention patent certificates, indicating a focus on innovation and potential growth in their product offerings [1]

Group 1 - The core point of the news is that Tailin Bio has recently obtained three invention patents through its wholly-owned subsidiaries, indicating a focus on innovation and development in the biotechnology sector [1] - The patents include a "microbial elution solution and its preparation method and application" and a "sterile connector and sterile connection method," showcasing the company's advancements in medical technology [1] - For the fiscal year 2024, Tailin Bio's revenue composition is projected to be 90.04% from the pharmaceutical industry and 9.96% from other businesses, highlighting the company's strong reliance on its core pharmaceutical operations [1] Group 2 - As of the latest report, Tailin Bio has a market capitalization of 3.6 billion yuan, reflecting its position in the market [2]

Core Viewpoint - Tailin Bio has announced the receipt of three invention patent certificates from the National Intellectual Property Administration, indicating advancements in its product offerings and potential for innovation in the biotechnology sector [1] Group 1: Patent Details - The patents include "a microbial elution solution and its preparation method and application" [1] - Another patent is for "a sterile connector and sterile connection method" [1] - The third patent pertains to "a method, system, and storage medium for improving the accuracy of pump quantitative injection" [1]

浙江泰林生物技术股份有限公司（以下简称"公司"）全资子公司浙江泰林 生命科学有限公司（以下简称"泰林生命科学"）、浙江泰林医学工程有限公司（以 下简称"泰林医学工程"）于近期共取得了 3 项发明专利证书，具体情况如下： | 序号 | 专利名称 | 专利类型 | 申请号 | 授权公告日 | 专利权人 | | --- | --- | --- | --- | --- | --- | | 1 | 一种微生物洗脱液及其配制方法 和应用 | 发明 | 2025110170952 | 2025/10/31 | 泰林生命科学 | | 2 | 一种无菌连接器及无菌连接方法 | 发明 | 2023110142050 | 2025/10/31 | 泰林医学工程 | | 3 | 一种泵定量加注精度的提升方法、 系统及存储介质 | 发明 | 2024110229307 | 2025/10/31 | 泰林医学工程 | 证券代码：300813 证券简称：泰林生物 公告编号：2025-082 浙江泰林生物技术股份有限公司 关于取得专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 ...

Company Overview - Zhejiang Tailin Biological Technology Co., Ltd. was listed on the Shenzhen Stock Exchange in January 2020, focusing on life science solutions, including biotechnology, precision medicine, pharmaceutical engineering, food safety, and new materials [3] - The company serves thousands of clients across various sectors, including pharmaceutical companies, food and drug inspection agencies, healthcare institutions, and research organizations [3] Market and Product Insights - The company is actively expanding its product applications in the semiconductor industry, with a focus on developing new technologies and products [4] - In 2025, the water ecology market is shifting towards comprehensive data, precise results, and practical new technologies, with an emphasis on risk management and monitoring [4] - Tailin's water ecology products include enzyme substrate detection systems and fully automated detection systems, addressing systemic needs in water monitoring and management [4] Financial Performance - The company's gross margin has improved significantly in the first half of 2025, primarily due to higher margins from its sterile production and contamination control equipment [5][6] - International business has seen notable growth, with higher unit prices and margins compared to domestic sales [6] Research and Development - R&D expenses account for 25% of the company's costs, focusing on life sciences, medical engineering, and analytical instruments [6] - Recent R&D priorities include water ecology detection, quality control in pharmaceutical health products, safety in major disease treatment drugs, and applications in the semiconductor sector [6]

Market Performance - The specialized equipment sector increased by 0.74% on November 3, with Tailin Bio leading the gains [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Top Gainers - Tailin Bio (300813) closed at 33.46, up 12.09% with a trading volume of 85,600 shares and a turnover of 285 million yuan [1] - Dahongli (300865) closed at 33.02, up 11.29% with a trading volume of 73,500 shares and a turnover of 235 million yuan [1] - Guojitongyong (600444) closed at 20.09, up 10.02% with a trading volume of 116,800 shares [1] - Dongfang Precision (002611) closed at 20.90, up 10.00% with a trading volume of 3.1185 million shares and a turnover of 6.358 billion yuan [1] Top Losers - Taidan Co. (003036) closed at 18.16, down 9.92% with a trading volume of 286,500 shares and a turnover of 542 million yuan [2] - Keda Manufacturing (66t0009) closed at 12.40, down 5.42% with a trading volume of 744,600 shares [2] - Ruitong Co. (603036) closed at 21.44, down 4.63% with a trading volume of 97,500 shares [2] Capital Flow - The specialized equipment sector experienced a net outflow of 406 million yuan from institutional investors, while retail investors saw a net inflow of 388 million yuan [2] - The top stocks by net inflow from retail investors included Lansi Heavy Industry (603169) with a net inflow of 2.19 billion yuan [3] - The top stocks by net outflow from institutional investors included Zhonghua Equipment (600579) with a net outflow of 32.43 million yuan [3]

Financial Performance - The company's operating revenue for the reporting period was 67,363,245.41 yuan, a decrease of 21.84% compared to the same period last year [2] - The net profit attributable to shareholders was 1,180,325.54 yuan, down 75.06% year-on-year [2] - The basic earnings per share decreased by 75.00% to 0.01 yuan, while diluted earnings per share dropped by 100.00% to 0.00 yuan [2] - The total assets at the end of the reporting period were 934,063,765.94 yuan, a decrease of 2.69% from the previous year [2] Cash Flow Analysis - The net cash flow from operating activities was 14,859,155.99 yuan, an increase of 171.73% compared to the previous period [7] - The net cash flow from investing activities was 18,597,586.88 yuan, a decrease of 34.57% year-on-year [7] - The net cash flow from financing activities was -40,384,964.10 yuan, a significant decrease of 954.70% compared to the previous period [7] Shareholder Information - The total number of ordinary shareholders and the top ten shareholders' holdings were detailed, with the largest shareholder holding 18,402,400 shares [9] - The company has a significant relationship between major shareholders, indicating potential influence on corporate governance [9] Changes in Financial Indicators - The company experienced a 49.04% decrease in cash and cash equivalents due to investments in structured deposits and wealth management products [6] - The accounts receivable increased, leading to a 245.94% rise in credit impairment losses [7] - The company reported a 90.80% decrease in other non-current assets, primarily due to a reduction in equipment prepayments [6]

Company Overview - Tailin Biological Technology Co., Ltd. is located in Hangzhou, Zhejiang Province, established on January 8, 2002, and listed on January 14, 2020. The company specializes in the research, manufacturing, and sales of microbial detection and control technology systems, organic analysis instruments, and other pharmaceutical equipment [1]. Business Segmentation - The main business revenue composition is as follows: microbial detection technology series products account for 41.12%, sterile production and contamination control equipment series products account for 40.78%, organic analysis technology series products account for 11.15%, and others account for 6.95% [1]. Stock Performance - On October 27, Tailin Biological's stock fell by 5.14%, trading at 30.44 yuan per share, with a transaction volume of 85.03 million yuan and a turnover rate of 3.58%. The total market capitalization is 3.689 billion yuan [1]. Fund Holdings - According to data from major fund holdings, one fund under Nuoan Fund has a significant position in Tailin Biological. The Nuoan Multi-Strategy Mixed A Fund (320016) increased its holdings by 286,000 shares in the second quarter, bringing the total to 511,200 shares, which represents 0.44% of the fund's net value, making it the fourth-largest holding [2]. Fund Performance - The Nuoan Multi-Strategy Mixed A Fund (320016) was established on August 9, 2011, with a latest scale of 1.399 billion yuan. Year-to-date returns are 68.76%, ranking 345 out of 8,226 in its category; one-year returns are 84.01%, ranking 158 out of 8,099; and since inception, the return is 225.7% [2]. Fund Management - The fund is managed by Kong Xianzheng and Wang Haichang. As of the latest update, Kong has been in position for 4 years and 336 days, with a total fund asset size of 4.607 billion yuan, achieving a best return of 84.01% and a worst return of -16.74% during his tenure. Wang has been in position for 3 years and 98 days, managing assets of 2.529 billion yuan, with a best return of 71.06% and a worst return of -18.8% [3].

Group 1 - The core point of the news is that Tailin Bio (300813.SZ) reported its Q3 2025 results, revealing a total of 7 institutional investors holding shares, which amounts to 9.9005 million shares or 8.17% of the total share capital, with a decline of 1.10 percentage points compared to the previous quarter [1] - Institutional investors include Qingdao Gaode Investment Partnership, Zhejiang Tailin Biotechnology Co., Ltd. - 2025 Employee Stock Ownership Plan, and UBS AG among others, indicating a diverse range of institutional interest [1] - The report also mentions that 23 public funds were not disclosed in this period compared to the previous quarter, including notable funds such as NuAn Duo Strategy Mixed A and China Europe CSI 300 Index Quantitative Enhancement A [1] Group 2 - From the foreign investment perspective, there was one new foreign institution disclosed this quarter, which is CITIC Securities Asset Management (Hong Kong) Co., Ltd. - Client Funds [2] - The report indicates that several foreign institutions, including BARCLAYS BANK PLC and Goldman Sachs, were not disclosed in this period compared to the previous quarter, suggesting a potential shift in foreign investment interest [2]